Enterprise Value (EV)
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Cytokinetics Inc., current enterprise value calculation
| Current share price (P) | |
| No. shares of common stock outstanding | |
| US$ in thousands | |
| Common equity (market value)1 | |
| Add: Preferred stock, $0.001 par value; issued and outstanding: none (per books) | |
| Total equity | |
| Add: Current portion of term loan (per books) | |
| Add: Short-term finance lease liabilities (per books) | |
| Add: Term loan, net, excluding current portion (per books) | |
| Add: Convertible notes, net (per books) | |
| Add: Long-term finance lease liabilities (per books) | |
| Total equity and debt | |
| Less: Cash and cash equivalents | |
| Less: Short-term investments | |
| Enterprise value (EV) | |
Based on: 10-K (reporting date: 2022-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Cytokinetics Inc., EV calculation
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
3 2022 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
- Equity Trends
- The common equity, which is equal to total equity, exhibited a consistent upward trajectory over the five-year period. It increased significantly from approximately $330 million at the end of 2018 to over $4.1 billion by the end of 2022. The most substantial growth occurred between 2020 and 2021, where the value more than doubled, indicating a strong increase in the company's net worth or market valuation during that period.
- Total Equity and Debt
- The combined total of equity and debt similarly showed a steady rise throughout the years reported. Starting from around $372 million in 2018, this measure increased to approximately $4.7 billion by 2022. The increments mirror the growth pattern seen in equity, suggesting the company likely took on additional debt alongside the increase in equity, helping to fuel expansion or investment activities.
- Enterprise Value (EV)
- Enterprise value also rose considerably over the period analyzed, moving from approximately $174 million in 2018 to nearly $3.9 billion in 2022. This metric grew more than twentyfold in these years, reflecting a strong increase in the company's overall valuation when combining market capitalization, debt, and cash equivalents. Notably, the EV trend aligns closely with the growth in equity and total capitalization, reinforcing the impression of overall company growth and increased market confidence.
- Overall Insights
- The data reveals significant growth in the financial scale and valuation of the entity. Each key measure—common equity, total equity and debt, and enterprise value—increased substantially, suggesting successful capital raising, increasing investor confidence, or value appreciation. The consistent growth across multiple valuation metrics signals a positive development in the company’s financial stature over the analyzed timeframe.